XHKG2256
Market cap398mUSD
Jan 07, Last price
4.61HKD
1D
-1.28%
1Q
36.80%
IPO
-62.82%
Name
Abbisko Cayman Ltd
Chart & Performance
P/E
—
P/S
153.17
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
19m
Net income
-432m
L-13.39%
CFO
-445m
L+29.32%
Earnings
Jun 18, 2025
Profile
Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, discovers and develops small molecule oncology therapies in the People's Republic of China. Its product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. The company's primary product candidates are ABSK011, a small molecule inhibitor of fibroblast growth factor receptor 4 for the treatment of advanced hepatocellular carcinoma with hyper-activation of FGF19/FGFR4 signaling; and ABSK091, a molecularly targeted product candidate for the treatment of multiple solid tumors, including urothelial cancer, gastric cancer, cholangiocarcinoma, and lung cancer. It also has other pipeline product candidates. The company was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 19,060 | ||||
Cost of revenue | 469,349 | 408,568 | |||
Unusual Expense (Income) | |||||
NOPBT | (450,289) | (408,568) | |||
NOPBT Margin | |||||
Operating Taxes | 2,685 | ||||
Tax Rate | |||||
NOPAT | (450,289) | (411,253) | |||
Net income | (431,583) -13.39% | (498,291) -72.39% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | (4,490) | (315) | |||
BB yield | 0.19% | 0.02% | |||
| Debt | |||||
Debt current | 10,610 | 9,968 | |||
Long-term debt | 60,838 | 81,182 | |||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | (1,939,281) | (2,261,473) | |||
| Cash flow | |||||
Cash from operating activities | (444,727) | (343,897) | |||
CAPEX | (9,603) | (22,746) | |||
Cash from investing activities | 378,524 | (216,575) | |||
Cash from financing activities | (16,105) | (20,814) | |||
FCF | (417,076) | (444,518) | |||
| Balance | |||||
Cash | 2,010,729 | 2,352,623 | |||
Long term investments | |||||
Excess cash | 2,009,776 | 2,352,623 | |||
Stockholders' equity | (3,907,022) | (3,151,997) | |||
Invested Capital | 5,923,848 | 5,519,910 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 647,226 | 620,676 | |||
Price | 3.65 13.71% | 3.21 -63.93% | |||
Market cap | 2,362,376 18.57% | 1,992,370 -4.69% | |||
EV | 423,095 | (269,103) | |||
EBITDA | (431,867) | (392,770) | |||
EV/EBITDA | 0.69 | ||||
Interest | 2,170 | 2,685 | |||
Interest/NOPBT | |||||